{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:00:12Z","timestamp":1787587212588,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI","award":["19K16414"],"award-info":[{"award-number":["19K16414"]}]},{"name":"Japanese Society of Nephrology and Pharmacotherapy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00228-019-02756-4","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T18:03:27Z","timestamp":1568225007000},"page":"1695-1704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2476-9191","authenticated-orcid":false,"given":"Naoto","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Chuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoyo","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingen","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Takechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"issue":"3","key":"2756_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/2042018816638223","volume":"7","author":"O Bamgbola","year":"2016","unstructured":"Bamgbola O (2016) Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab 7(3):136\u2013147. \nhttps:\/\/doi.org\/10.1177\/2042018816638223","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"9","key":"2756_CR2","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","volume":"68","author":"S Elyasi","year":"2012","unstructured":"Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A (2012) Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68(9):1243\u20131255. \nhttps:\/\/doi.org\/10.1007\/s00228-012-1259-9","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2756_CR3","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","volume":"29","author":"MN Jeffres","year":"2007","unstructured":"Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH (2007) A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 29(6):1107\u20131115. \nhttps:\/\/doi.org\/10.1016\/j.clinthera.2007.06.014","journal-title":"Clin Ther"},{"issue":"4","key":"2756_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/600884","volume":"49","author":"TP Lodise","year":"2009","unstructured":"Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL (2009) Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49(4):507\u2013514. \nhttps:\/\/doi.org\/10.1086\/600884","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2756_CR5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/aac.01568-12","volume":"57","author":"SJ van Hal","year":"2013","unstructured":"van Hal SJ, Paterson DL, Lodise TP (2013) Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 57(2):734\u2013744. \nhttps:\/\/doi.org\/10.1128\/aac.01568-12","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2756_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijantimicag.2018.03.024","volume":"52","author":"C Balci","year":"2018","unstructured":"Balci C, Uzun O, Arici M, Hayran SA, Yuce D, Unal S (2018) Nephrotoxicity of piperacillin\/tazobactam combined with vancomycin: should it be a concern? Int J Antimicrob Agents 52(2):180\u2013184. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2018.03.024","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"2756_CR7","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s11255-018-1870-5","volume":"50","author":"XY Chen","year":"2018","unstructured":"Chen XY, Xu RX, Zhou X, Liu Y, Hu CY, Xie XF (2018) Acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam administration: a systematic review and meta-analysis. Int Urol Nephrol 50(11):2019\u20132026. \nhttps:\/\/doi.org\/10.1007\/s11255-018-1870-5","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"2756_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1248\/bpb.b15-00774","volume":"39","author":"N Okada","year":"2016","unstructured":"Okada N, Fushitani S, Azuma M, Nakamura S, Nakamura T, Teraoka K, Watanabe H, Abe M, Kawazoe K, Ishizawa K (2016) Clinical evaluation of pharmacist interventions in patients treated with anti-methicillin-resistant Staphylococcus aureus agents in a hematological ward. Biol Pharm Bull 39(2):295\u2013300. \nhttps:\/\/doi.org\/10.1248\/bpb.b15-00774","journal-title":"Biol Pharm Bull"},{"key":"2756_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijantimicag.2005.08.001","volume":"26","author":"K Tamura","year":"2005","unstructured":"Tamura K (2005) Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents 26 Suppl 2: S123-127; discussion S133-140:123\u2013127. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2005.08.001","journal-title":"Int J Antimicrob Agents"},{"key":"2756_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cca.2014.11.027","volume":"440","author":"Y Suzuki","year":"2015","unstructured":"Suzuki Y, Tokimatsu I, Morinaga Y, Sato Y, Takano K, Kohno K, Ogata M, Hiramatsu K, Itoh H, Kadota J (2015) A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy. Clin Chim Acta 440:183\u2013187. \nhttps:\/\/doi.org\/10.1016\/j.cca.2014.11.027","journal-title":"Clin Chim Acta"},{"issue":"3","key":"2756_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","volume":"19","author":"K Matsumoto","year":"2013","unstructured":"Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, Okada K, Igarashi M, Kobayashi M, Hamada Y, Kimura M, Nishi Y, Tanigawara Y, Kimura T (2013) Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 19(3):365\u2013380. \nhttps:\/\/doi.org\/10.1007\/s10156-013-0599-4","journal-title":"J Infect Chemother"},{"issue":"6","key":"2756_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982\u2013992. \nhttps:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2756_CR13","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179\u2013c184. \nhttps:\/\/doi.org\/10.1159\/000339789","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"2756_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijantimicag.2010.10.013","volume":"37","author":"A Wong-Beringer","year":"2011","unstructured":"Wong-Beringer A, Joo J, Tse E, Beringer P (2011) Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 37(2):95\u2013101. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2010.10.013","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"2756_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/cir124","volume":"52","author":"R Kullar","year":"2011","unstructured":"Kullar R, Davis SL, Levine DP, Rybak MJ (2011) Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 52(8):975\u2013981. \nhttps:\/\/doi.org\/10.1093\/cid\/cir124","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2756_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/cid\/cir895","volume":"54","author":"RG Wunderink","year":"2012","unstructured":"Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54(5):621\u2013629. \nhttps:\/\/doi.org\/10.1093\/cid\/cir895","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2756_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/ftd.0000000000000459","volume":"40","author":"M Chuma","year":"2018","unstructured":"Chuma M, Makishima M, Imai T, Tochikura N, Suzuki S, Kuwana T, Sawada N, Komatsu T, Sakaue T, Kikuchi N, Yoshida Y, Kinoshita K (2018) Relationship between initial vancomycin trough levels and early-onset vancomycin-associated nephrotoxicity in critically ill patients. Ther Drug Monit 40(1):109\u2013114. \nhttps:\/\/doi.org\/10.1097\/ftd.0000000000000459","journal-title":"Ther Drug Monit"},{"issue":"5","key":"2756_CR18","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1128\/aac.36.5.1062","volume":"36","author":"R Ramphal","year":"1992","unstructured":"Ramphal R, Bolger M, Oblon DJ, Sherertz RJ, Malone JD, Rand KH, Gilliom M, Shands JW Jr, Kramer BS (1992) Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 36(5):1062\u20131067. \nhttps:\/\/doi.org\/10.1128\/aac.36.5.1062","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2756_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1086\/500139","volume":"42","author":"B Jaksic","year":"2006","unstructured":"Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ (2006) Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42(5):597\u2013607. \nhttps:\/\/doi.org\/10.1086\/500139","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2756_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jpids\/piy030","volume":"8","author":"Kathryn M Cook","year":"2018","unstructured":"Cook KM, Gillon J, Grisso AG, Banerjee R, Jimenez-Truque N, Phillips EJ (2019) Van driest SL (2018) incidence of nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin-tazobactam or cefepime: a cohort study. J Pediatr Infect Dis Soc. \nhttps:\/\/doi.org\/10.1093\/jpids\/piy030","journal-title":"Journal of the Pediatric Infectious Diseases Society"},{"issue":"1","key":"2756_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13054-017-1899-3","volume":"21","author":"G Hundeshagen","year":"2017","unstructured":"Hundeshagen G, Herndon DN, Capek KD, Branski LK, Voigt CD, Killion EA, Cambiaso-Daniel J, Sljivich M, De Crescenzo A, Mlcak RP, Kinsky MP, Finnerty CC, Norbury WB (2017) Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients. Crit Care 21(1):318. \nhttps:\/\/doi.org\/10.1186\/s13054-017-1899-3","journal-title":"Crit Care"},{"issue":"4","key":"2756_CR22","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.bbmt.2017.12.799","volume":"24","author":"AB Clemmons","year":"2018","unstructured":"Clemmons AB, Bech CF, Pantin J, Ahmad I (2018) Acute kidney injury in hematopoietic cell transplantation patients receiving vancomycin and piperacillin\/tazobactam versus vancomycin and cefepime. Biol Blood Marrow Transpl 24(4):820\u2013826. \nhttps:\/\/doi.org\/10.1016\/j.bbmt.2017.12.799","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8629891","key":"2756_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/8629891","volume":"2019","author":"HA Personett","year":"2019","unstructured":"Personett HA, Kayhart BM, Barreto EF, Tosh P, Dierkhising R, Mara K, Leung N (2019) Renal recovery following liposomal amphotericin B-induced nephrotoxicity. Int J Nephrol 2019(8629891):1\u20138. \nhttps:\/\/doi.org\/10.1155\/2019\/8629891","journal-title":"Int J Nephrol"},{"key":"2756_CR24","doi-asserted-by":"publisher","unstructured":"Stanzani M, Vianelli N, Cavo M, Maritati A, Morotti M, Lewis RE (2017) Retrospective cohort analysis of liposomal amphotericin B nephrotoxicity in patients with hematological malignancies. Antimicrob Agents Chemother 61(9). \nhttps:\/\/doi.org\/10.1128\/aac.02651-16","DOI":"10.1128\/aac.02651-16"},{"issue":"2","key":"2756_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clinthera.2017.12.006","volume":"40","author":"N Okada","year":"2018","unstructured":"Okada N, Azuma M, Imanishi M, Zamami Y, Kirino Y, Nakamura T, Teraoka K, Abe M, Ishizawa K (2018) Potential usefulness of early potassium supplementation for preventing severe hypokalemia induced by liposomal amphotericin B in hematologic patients: a retrospective study. Clin Ther 40(2):252\u2013260. \nhttps:\/\/doi.org\/10.1016\/j.clinthera.2017.12.006","journal-title":"Clin Ther"},{"issue":"12","key":"2756_CR26","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1093\/cid\/cix675","volume":"65","author":"RR Watkins","year":"2017","unstructured":"Watkins RR, Deresinski S (2017) Increasing evidence of the nephrotoxicity of piperacillin\/tazobactam and vancomycin combination therapy-what is the clinician to do? Clin Infect Dis 65(12):2137\u20132143. \nhttps:\/\/doi.org\/10.1093\/cid\/cix675","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2756_CR27","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1517\/14740338.2012.721775","volume":"11","author":"I Karimzadeh","year":"2012","unstructured":"Karimzadeh I, Farsaei S, Khalili H, Dashti-Khavidaki S (2012) Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity? Expert Opin Drug Saf 11(6):969\u2013983. \nhttps:\/\/doi.org\/10.1517\/14740338.2012.721775","journal-title":"Expert Opin Drug Saf"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02756-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T17:18:03Z","timestamp":1599758283000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02756-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2756"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02756-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"assertion":[{"value":"12 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The survey content and methods to protect personal information were approved by the Tokushima University Hospital Ethics Committee and were in accordance with the stipulations on the handling of patient personal information (Ethics Committee Registration Number: 3245).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}